Methylprednisolone
Methylprednisolone has been studied in 11 papers since 2016: 1 trial and 2 observational studies in people, 2 in animals, 2 reviews; 5 in the past year. It is an approved medicine. The newest paper, Nov 17, 2026: “Painful Non‐Diabetic Lumbosacral Radiculoplexus Neuropathy Following Tirzepatide Exposure: A Case Report”.
1 new paper in 30 daysSee all 17 papers on methylprednisolone
At a glance
The findings reach people, from one lab or study. 3 independent labs in 3 countries; 413 trials, 2 about aging, 130 with no results posted.
“methylprednisolone greatly reduced the incidence of delirium at 72 hours following surgery (9 [10.7%] vs 20 [23.8%], p = .03, OR = 2.22 [95% CI 1.05-4.59])”
None of its findings points the other way.
- 3 independent labs in 3 countries
- 413 trials, 2 about aging, 130 with no results posted
- Funders: Medical Science and Technology Project of Zhejiang Province and 1 more
- Human trial1
- Humans2
- Animals2
Studies in people
1 study gave methylprednisolone to people and measured what changed.
| What changed | Design | People | Source |
|---|---|---|---|
down: Lowers the risk of postoperative delirium9 (10.7%) vs 20 (23.8%) no change: Has no effect on delirium severityp = .14 down: Decreases SYNDECAN-1p < .05 and p < .01 | Randomized trialsingle preoperative dose | 168 people65-80 yearsOlder adults; postoperative delirium following laparoscopic gastrointestinal surgery | The journals of gerontology. Series A, Biological sciences and medical sciences, Aug 24, 2021 |
What did studies of methylprednisolone find?
5Studies of methylprednisolone measured 5 outcomes, among them seizures, BDNF and SYNDECAN-1.
Seizures
downin humans1
1 study
Seizures
downin humans1
Methylprednisolone is linked with lower seizures in tirzepatide-associated limbic encephalitis with status epilepticus (complete control within 24 h).
“High-dose intravenous methylprednisolone (2 g/day × 3 days, then tapered) granted complete control of seizures within 24 h.”
Humansin tirzepatide-associated limbic encephalitis with status epilepticus2 g/day × 3 days, then tapered3 days, then taperedmalesn = 1
Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
BDNF
upin humans1
1 study
BDNF
upin humans1
Methylprednisolone increases BDNF in humans (older patients undergoing gastrointestinal surgery) (p < .01).
“while the level of BDNF in Group M was higher than that in Group C (p < .01).”
Human trialolder patients undergoing gastrointestinal surgerycirculating2 mg/kgsingle preoperative dosen = 168
The journals of gerontology. Series A, Biological sciences and medical sciences
SYNDECAN-1
downin humans1
1 study
SYNDECAN-1
downin humans1
Methylprednisolone decreases SYNDECAN-1 in humans (older patients undergoing gastrointestinal surgery) (p < .05 and p < .01).
“The levels of heparan sulfate, syndecan-1, and TNF-α in Group M were lower than that in Group C (p < .05 and p < .01)”
Human trialolder patients undergoing gastrointestinal surgerycirculating2 mg/kgsingle preoperative dosen = 168
The journals of gerontology. Series A, Biological sciences and medical sciences
Delirium severity
no changein humans1
1 study
Delirium severity
no changein humans1
Methylprednisolone showed no clear effect on delirium severity in humans (older patients undergoing gastrointestinal surgery) (p = .14).
“No between-group difference was found in the cumulative CAM-S score (p = .14).”
Human trialolder patients undergoing gastrointestinal surgery2 mg/kgsingle preoperative dosen = 168
The journals of gerontology. Series A, Biological sciences and medical sciences
Taurine
upin reviews1
1 study
Taurine
upin reviews1
Methylprednisolone increases taurine in spinal cord injury therapy.
“Higher level of taurine has been also recorded in SCI therapy using, known clinical agent methyl prednisolone (MP)”
Reviewin spinal cord injury therapy
Role of taurine in spinal cord injury
Current neurovascular research
What is methylprednisolone linked with?
4Studies link methylprednisolone with 4 measures, among them KL, CYP24A1 and TRPV5.
KL
mixedin O. aries1
1 study
KL
mixedin O. aries1
Methylprednisolone is associated with KL in O. aries after adjustment for repeated measures.
“Differences in klotho expression were most marked after adjustment for repeated measures (p = 0.1).”
Animalsafter adjustment for repeated measureskidneyfemales
Expression of Renal Vitamin D and Phosphatonin-Related Genes in a Sheep Model of Osteoporosis
Animals : an open access journal from MDPI
CYP24A1
mixedin O. aries1
1 study
CYP24A1
mixedin O. aries1
Methylprednisolone is associated with CYP24A1 in ovariectomized sheep treated for 2 months and euthanized at 5 months.
“Ovariectomized sheep treated with glucocorticoids for 2 months followed by euthanasia at 5 months showed significant differences in TRPV5, CYP24A1 and klotho gene expression compared to other groups.”
Animalsin ovariectomized sheep treated for 2 months and euthanized at 5 monthskidney2 months of treatment, euthanized at 5 monthsfemales
Expression of Renal Vitamin D and Phosphatonin-Related Genes in a Sheep Model of Osteoporosis
Animals : an open access journal from MDPI
TRPV5
mixedin O. aries1
1 study
TRPV5
mixedin O. aries1
Methylprednisolone is associated with TRPV5 in ovariectomized sheep treated for 2 months and euthanized at 5 months.
“Ovariectomized sheep treated with glucocorticoids for 2 months followed by euthanasia at 5 months showed significant differences in TRPV5, CYP24A1 and klotho gene expression compared to other groups.”
Animalsin ovariectomized sheep treated for 2 months and euthanized at 5 monthskidney2 months of treatment, euthanized at 5 monthsfemales
Expression of Renal Vitamin D and Phosphatonin-Related Genes in a Sheep Model of Osteoporosis
Animals : an open access journal from MDPI
Postoperative delirium
downin humans1
1 study
Postoperative delirium
downin humans1
Methylprednisolone lowers the risk of postoperative delirium in humans (postoperative delirium following laparoscopic gastrointestinal surgery) (9 (10.7%) vs 20 (23.8%)).
“methylprednisolone greatly reduced the incidence of delirium at 72 hours following surgery (9 [10.7%] vs 20 [23.8%], p = .03, OR = 2.22 [95% CI 1.05-4.59])”
Human trialpostoperative delirium following laparoscopic gastrointestinal surgerycirculating2 mg/kgsingle preoperative dosen = 168
The journals of gerontology. Series A, Biological sciences and medical sciences
Has methylprednisolone been tested in people?
2 of 413 about agingYes: 1 trial and 2 observational studies in people have been published, and 413 trials are registered.
About aging
Phase 4Recruiting
Phase 3Withdrawn
Approved
Oct 24, 1957Arthritis, Psoriatic, Arthritis, Rheumatoid, Bursitis, Dermatomyositis, Erythema Multiforme, Lupus Erythematosus, Systemic, Mycosis Fungoides, Osteoarthritis, Spondylitis, Ankylosing, Tenosynovitis, psoriasis, pemphigus, dermatitis, juvenile rheumatoid arthritis, acute gouty arthritis, Hypercalcemia, synovitis, post-traumatic osteoarthritis, seborrheic dermatitis, adrenocortical insufficiency, thyroiditis, congenital adrenal hyperplasia, perennial allergic rhinitis, drug hypersensitivity, Colitis, Ulcerative, Multiple Sclerosis, Nephrotic Syndrome, Proteinuria, Thrombocytopenia, pulmonary tuberculosis, atopic dermatitis, sarcoidosis, lupus erythematosus, aspiration pneumonitis, hemolytic anemia, Lymphomas, acute leukemia, drug hypersensitivity reactions, idiopathic thrombocytopenic purpura, tuberculous meningitis, contact dermatitis, bronchial asthma, berylliosis
May 18, 1959Asthma, Colitis, Ulcerative, Erythema Multiforme, Mycosis Fungoides, atopic dermatitis, pemphigus, dermatitis, Hypercalcemia, hemolytic anemia, adrenocortical insufficiency, drug hypersensitivity reactions, idiopathic thrombocytopenic purpura, contact dermatitis, thyroiditis, congenital adrenal hyperplasia, Arthritis, Psoriatic, Arthritis, Rheumatoid, Dermatomyositis, Lupus Erythematosus, Systemic, Multiple Sclerosis, Proteinuria, Spondylitis, Ankylosing, Thrombocytopenia, Uveitis, pulmonary tuberculosis, sarcoidosis, polymyositis, juvenile rheumatoid arthritis, lupus erythematosus, acute gouty arthritis, Lymphomas, tuberculous meningitis, idiopathic nephrotic syndrome, berylliosis, ocular inflammatory conditions, temporal arteritis
May 27, 1959Asthma, Colitis, Ulcerative, Erythema Multiforme, Mycosis Fungoides, Thrombocytopenia, atopic dermatitis, pemphigus, dermatitis, Hypercalcemia, hemolytic anemia, adrenocortical insufficiency, drug hypersensitivity reactions, contact dermatitis, thyroiditis, congenital adrenal hyperplasia, Alopecia Areata, Arthritis, Psoriatic, Arthritis, Rheumatoid, Bursitis, Dermatomyositis, Lupus Erythematosus, Systemic, Osteoarthritis, Proteinuria, Spondylitis, Ankylosing, Tenosynovitis, Uveitis, pulmonary tuberculosis, sarcoidosis, polymyositis, juvenile rheumatoid arthritis, lupus erythematosus, acute gouty arthritis, synovitis, lichen planus, cerebral edema, Lymphomas, lichen simplex chronicus, tuberculous meningitis, granuloma annulare, idiopathic nephrotic syndrome, discoid lupus erythematosus, berylliosis, ocular inflammatory conditions, temporal arteritis
Jun 21, 1960Discontinued
Dec 21, 1977Discontinued
Repurposing
Phase 4Completed1 trial
Phase 3Recruiting1 trial
Phase 4Status unknown1 trial
Chronic obstructive pulmonary disease
Phase 4Terminated2 trials
Phase 4Completed12 trials
Phase 3Active, not recruiting1 trial
40 of 203Fewer
Every condition in trials
Adverse effects
Phase 4Completed2 trials
Cluster Headache
Phase 4Completed2 trials
Glucocorticoids
Phase 4Status unknown2 trials
Advanced follicular lymphoma
Phase 4Results posted1 trial
Cardiopulmonary bypass
Phase 4Status unknown1 trial
Immune reconstitution inflammatory syndrome
Phase 4Terminated1 trial
40 of 60Fewer
Readouts due
- Feb 2027
Phase 1/2 Clinical Trial of PR001 in Infants With Type 2 Gaucher Disease (PROVIDE)
Phase 1/2Active, not recruiting
- Apr 1, 2027
A Trial of Selinexor, Ruxolitinib and Methylprednisolone
Phase 1Recruiting
- Apr 1, 2027
- Jul 31, 2027
- Sep 2027
- Oct 31, 2027
Stopped
NCT02921555TerminatedUlcerative colitis
slow recruitment rate
NCT03704584TerminatedTenosynovitis
Enrollment and study activities were initially suspended due to COVID-19. The investigator has also left Emory and the study will not resume.
NCT01281748TerminatedChronic obstructive pulmonary disease
Low rate of enrollment
NCT01742338TerminatedChronic obstructive pulmonary disease
Lack of research staff to recruit participants
NCT03898154TerminatedWrist fracture
Study discontinued due to departure of research staff and changes in institutional priorities. Study failed to meet enrollment goals of 200 total participants (n=100/study arm)
NCT04393207TerminatedAcute pain
Slow/low recruitment, unable to recruit
All 34Fewer
Who is developing methylprednisolone?
3 companies: Astellas Pharma, Incyte and Oncotherapeutics.
Trial sponsors
Company13 trialsPhase 43,444 people
Company5 trialsPhase 4732 people
Company3 trialsPhase 41,558 people
Company3 trialsPhase 4297 people
Company3 trialsPhase 498 people
Company2 trialsPhase 4177 people
Company1 trialPhase 4169 people
Company1 trialPhase 4160 people